Considering Precision BioSciences Inc. (DTIL) as a potential investment: What Should You Do?

After finishing at $0.93 in the prior trading day, Precision BioSciences Inc. (NASDAQ: DTIL) closed at $0.89, down -4.36%. In other words, the price has decreased by -$0.0405 from its previous closing price. On the day, 734069 shares were traded. DTIL stock price reached its highest trading level at $0.9553 during the session, while it also had its lowest trading level at $0.8644.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".



Our goal is to gain a better understanding of DTIL by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.30 and its Current Ratio is at 3.30. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.37.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BMO Capital Markets on June 17, 2022, initiated with a Outperform rating and assigned the stock a target price of $7.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 06 when Scimeca Dario sold 12,172 shares for $1.07 per share. The transaction valued at 13,024 led to the insider holds 50,063 shares of the business.

List Alan sold 9,473 shares of DTIL for $10,136 on Mar 06. The Chief Medical Officer now owns 38,240 shares after completing the transaction at $1.07 per share. On Oct 17, another insider, Amoroso Michael, who serves as the President and CEO of the company, sold 11,006 shares for $1.32 each. As a result, the insider received 14,528 and left with 13,202 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 5.32 while its Price-to-Book (P/B) ratio in mrq is 1.65.

Stock Price History:

Over the past 52 weeks, DTIL has reached a high of $3.93, while it has fallen to a 52-week low of $0.90. The 50-Day Moving Average of the stock is 1.1800, while the 200-Day Moving Average is calculated to be 1.3933.

Shares Statistics:

The stock has traded on average 619.08K shares per day over the past 3-months and 532.26k shares per day over the last 10 days, according to various share statistics. A total of 111.21M shares are outstanding, with a floating share count of 91.97M. Insiders hold about 1.90% of the company’s shares, while institutions hold 47.40% stake in the company. Shares short for DTIL as of Jan 30, 2023 were 753.77k with a Short Ratio of 0.78M, compared to 1M on Dec 29, 2022. Therefore, it implies a Short% of Shares Outstanding of 0.68% and a Short% of Float of 0.71%.

Earnings Estimates

Its stock is currently analyzed by 8 different market analysts. On average, analysts expect EPS of -$0.21 for the current quarter, with a high estimate of -$0.09 and a low estimate of -$0.26, while EPS last year was -$0.38. The consensus estimate for the next quarter is -$0.24, with high estimates of -$0.22 and low estimates of -$0.28.

Analysts are recommending an EPS of between -$1.05 and -$1.35 for the fiscal current year, implying an average EPS of -$1.22. EPS for the following year is -$0.93, with 8 analysts recommending between -$0.51 and -$1.35.

Revenue Estimates

7 analysts predict $6.81M in revenue for the current quarter. It ranges from a high estimate of $11.25M to a low estimate of $2.5M. As of the current estimate, Precision BioSciences Inc.’s year-ago sales were $6.34M, an estimated increase of 7.40% from the year-ago figure. For the next quarter, 3 analysts are estimating revenue of $6.87M, an increase of 107.10% over than the figure of $7.40% in the same quarter last year. There is a high estimate of $7.5M for the next quarter, whereas the lowest estimate is $6.12M.

A total of 9 analysts have provided revenue estimates for DTIL’s current fiscal year. The highest revenue estimate was $25.8M, while the lowest revenue estimate was $17M, resulting in an average revenue estimate of $21.59M. In the same quarter a year ago, actual revenue was $115.53M, down -81.30% from the average estimate. Based on 9 analysts’ estimates, the company’s revenue will be $30.91M in the next fiscal year. The high estimate is $85M and the low estimate is $10M. The average revenue growth estimate for next year is up 43.20% from the average revenue estimate for this year.